During the past decade, DRK Kliniken Berlin Westend conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 9 clinical trials were completed, i.e. on average, 34.6% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 8 clinical trials were completed. i.e. 88.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "DRK Kliniken Berlin Westend" #1 sponsor was "Celgene" with 5 trials, followed by "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Actelion" with 2 trials sponsored and "Takeda" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "DRK Kliniken Berlin Westend" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "Centre Hospitalier Universitaire de Besancon" with 1 trials as a collaborator, "Charite University, Berlin, Germany" with 1 trials as a collaborator, "Ferrer Internacional S.A." with 1 trials as a collaborator and "General University Hospital, Prague" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "DRK Kliniken Berlin Westend" are "Pulmonary Arterial Hypertension" (7 trials), "Ulcerative Colitis" (6 trials), "Crohn Disease" (3 trials), "Crohn's Disease" (3 trials) and "Myocardial Infarction" (2 trials). Many other conditions were trialed in "DRK Kliniken Berlin Westend" in a lesser frequency.

Most popular intervention types in "DRK Kliniken Berlin Westend" are "Drug" (29 trials), "Device" (3 trials), "Other" (3 trials), "Biological" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "GED-0301" (3 trials), "Sotatercept" (3 trials), "Etrolizumab" (2 trials) and "RPC1063" (2 trials). Other intervention names were less common.

The vast majority of trials in "DRK Kliniken Berlin Westend" are 30 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "DRK Kliniken Berlin Westend". undefined are not yet recruiting, 3 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in DRK Kliniken Berlin Westend, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in DRK Kliniken Berlin Westend, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".